KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Esperion Therapeutics (ESPR) Shares Outstanding (2016 - 2026)

Esperion Therapeutics filings provide 9 years of Shares Outstanding readings, the most recent being $245.2 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 25.2% to $245.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $245.2 million, a 25.2% increase, with the full-year FY2025 number at $245.2 million, up 25.2% from a year prior.
  • Shares Outstanding hit $247.2 million in Q4 2025 for Esperion Therapeutics, up from $205.4 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $247.2 million in Q4 2025 to a low of $26.2 million in Q1 2021.
  • Median Shares Outstanding over the past 5 years was $106.5 million (2023), compared with a mean of $122.7 million.
  • Biggest five-year swings in Shares Outstanding: decreased 5.32% in 2021 and later soared 167.7% in 2022.
  • Esperion Therapeutics' Shares Outstanding stood at $60.9 million in 2021, then grew by 22.49% to $74.6 million in 2022, then surged by 58.52% to $118.2 million in 2023, then surged by 65.68% to $195.9 million in 2024, then grew by 25.2% to $245.2 million in 2025.
  • The last three reported values for Shares Outstanding were $245.2 million (Q4 2025), $205.4 million (Q3 2025), and $200.2 million (Q2 2025) per Business Quant data.